Empagliflozin - CAS# 864070-44-0 24726A genome replication

genome replication

also known as Olbemox and K-9321

GSK-J4 could significant reduce LPS-induced pro-inflammatory cytokine production in primary human macrophages (IC50 ~9 μM for the inhibition of TNFα release)

Murayama N

216227-54-2

Empagliflozin - CAS# 864070-44-0 24726A genome replicationEmpagliflozin, also known as BI10773 (trade name Jardiance), is drug approved for the treatment of type 2 diabetes in adults in 2014. It was developed by Boehringer Ingelheim and Eli Lilly and Company. Empagliflozin is an inhibitor of the sodium glucose co transporter 2 (SGLT 2), and causes sugar in the blood to be absorbed by the kidneys and eliminated in urine. Empagliflozin is an inhibitor of the sodium glucose co transporter 2 (SGLT 2), which is